ErbB4 promotes M2 activation of macrophages in idiopathic pulmonary fibrosis
Open Access
- 1 January 2023
- journal article
- research article
- Published by Walter de Gruyter GmbH in Open Life Sciences
- Vol. 18 (1) , 20220692
Abstract
Idiopathic pulmonary fibrosis (IPF) is the most common and fatal diffuse fibrotic lung disease accompanied by macrophage M2 activation. ErbB4 is involved in and affects the process of inflammation. In this study, we determined that the mRNA level and protein expression of ErbB4 and M2 cytokine members were increased in the serum of IPF patients. In mouse alveolar macrophage MH-S cells, after knocking down ErbB4 by siRNA, the mRNA level and protein expression of M2 activator induced by interleukin (IL)-4 were decreased compared with the control group. Activating by ErbB4 agonist neuromodulatory protein (NRG)-1, IL-4-induced M2 program was promoted. Mechanistically, treated with NRG-1 in MH-S cells, the phosphorylation level of Akt did not change, while the phosphorylation level of ERK increased. Using SCH772984 to inhibit ERK pathway, the increasing IL-4-induced M2 activation by NRG-1 was inhibited, and the high level of M2 activator protein expression and mRNA expression was restored. Collectively, our data support that ErbB4 and M2 programs are implicated in IPF, and ErbB4 participates in the regulation of M2 activation induced by IL-4 through the ERK pathway.Keywords
This publication has 32 references indexed in Scilit:
- Inhibitory actions of the NRG-1/ErbB4 pathway in macrophages during tissue fibrosis in the heart, skin, and lungAmerican Journal of Physiology-Heart and Circulatory Physiology, 2017
- Pulmonary fibrosis, part I: epidemiology, pathogenesis, and diagnosisExpert Review of Respiratory Medicine, 2017
- ErbB4 signaling stimulates pro-inflammatory macrophage apoptosis and limits colonic inflammationCell Death & Disease, 2017
- Neuregulin1 alpha activates migration of neuronal progenitors expressing ErbB4Molecular and Cellular Neuroscience, 2016
- An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of Idiopathic Pulmonary Fibrosis: An Update of the 2011 Clinical Practice GuidelineAmerican Journal of Respiratory and Critical Care Medicine, 2015
- Idiopathic pulmonary fibrosis: An updateAnnals of Medicine, 2015
- Neuregulin-ErbB4 signaling in the developing lung alveolus: a brief reviewJournal of Cell Communication and Signaling, 2014
- Strategies for treating idiopathic pulmonary fibrosisNature Reviews Drug Discovery, 2010
- The ERBB3 receptor in cancer and cancer gene therapyCancer Gene Therapy, 2008
- Molecular Targets in Pulmonary FibrosisChest, 2007